Institutional accumulation regime. Strong business quality combined with supportive market trend. Valuations remain balanced and supported by current metrics.
SENTINEL REVIEW
Aarti Pharmalabs Limited (AARTIPHARM)โขUpdated yesterday
๐จ Structural Deterioration Signature: In FY2026, Aarti Pharmalabs Limited is experiencing severe earnings quality deterioration, marked by a 35.9% YoY decline in reported net profit to โน174.7 Cr from โน272.4 Cr, compounded by a 7.5% YoY compression in EBIT margins to 12.9%. This is accompanied by a 21.0% YoY contraction in operating cash flow to โน261.9 Cr, reflecting intensifying operational friction. This structural strain is driven by persistent margin compression, elevated capex of 51.7% of revenue, and a 73.0% YoY expansion in total debt to โน685.6 Cr, pushing debt-to-equity to 0.32. Concurrently, receivable days surged to 87.9, and inventory-revenue divergence widened to 1.56x, indicating liquidity pressure and working capital strain.
- โRisk score improved (QoQ change: -5 pts)
- โProfitability margins remain stressed
- โNew risk trigger: Universal Inventory Divergence (+9.6 pts)
- โGrowth expectations are demanding
- โMarket structure is strong
- โInstitutional flow regime is Accumulation (0.46ฯ)
- โShare price is down -7.5% this quarter (from โน953.75 on 30 Sept to โน881.95)
- ๐ดInvestigate Industrial Margin Stress and balance sheet impact
- ๐ Track earnings quality and working capital trends in next filing
- ๐ขMaintain routine quarterly surveillance; no governance escalation required
- 9.9 ptsGrowth Sustainability
- 9.5 ptsBalance Sheet Stress
- 7.6 ptsGovernance
Divergence Radar
Structural Matrix
Risk vs Price TimelineVisualizing the historical relationship between the structural risk score and stock price movement over time.
| Duration | Perf. | Sector Avg | Divergence |
|---|---|---|---|
| 1 Week | +4.59% | -1.46% | +6.05% |
| 1 Month | -3.51% | -6.69% | +3.18% |
| 6 Months | +19.14% | +6.82% | +12.32% |
| 1 Year | +4.84% | +8.93% | -4.08% |
| 2 Year | +40.62% | +47.64% | -7.02% |
| 3 Year | +122.39% | +125.5% | -3.11% |
Business Analysis Methodology
Business analysis focuses on structural risk inside the company. Flagium monitors earnings quality, balance sheet strength, liquidity, governance, competitive position, and growth sustainability to identify areas where risk may be increasing or decreasing before it becomes obvious in reported results.
Financial profile remains stable for now. Pressure is receding in growth sustainability. This suggests the risk profile is currently stabilizing. Risk levels are improving.
Risk Score Composition
Investment Risk Thesis
Current risk score has risen from 6 โ 27 over 12 quarters.
- Operating profit margins
- Inventory turnover
Risk Drivers (Active Warnings)
Primary Driver & Insights
Asset turnover is slowing down due to inventory accumulation. This indicates potential channel stuffing or weaker demand in core product segments.
Active Risk Objects (10)Free Preview (2 of 10)
AARTIPHARM: Inventory growth outpaced Revenue growth by +20.6 pp (Inventory holding ratio increased +19.9%).
Slight build-up in inventory detected. Monitor for slowing sales momentum.
AARTIPHARM: Raw material costs consumed an additional 6.2% of revenue YoY.
Margins are in freefall. Operating costs are growing significantly faster than revenue.
Unlock All 10 Forensic Signals (8 Additional Warnings Gated)
Free accounts preview the top 2 highest-impact warning signals. Upgrade to Flagium Pro to inspect all 10 active forensic detectors, multi-quarter duration streaks, and financial stress metrics for Aarti Pharmalabs Limited.
Statutory Note: Forensic signals are algorithmic quantitative observations derived from publicly filed XBRL disclosures and do not constitute allegations of legal misconduct or investment recommendations.
Unlock Interactive Signal Evidence Dossier
Access complete multi-quarter financial evidence, 5-KPI snapshot strips, diagnostic hypotheses, and 1-page forensic PDF dossiers for Aarti Pharmalabs Limited.
Structural Risk Attribution
Deterministic quarter-on-quarter causal decomposition grounded in statutory exchange filings.
Structural History ยท Last 12 QuartersHistorical Trajectory (12Q)
Risk improved moderately (-5.0 pts), driven by overall risk reduction across core indicators, partially offset by new Universal Inventory Divergence (+9.6 pts) and new Promoter Stake Dilution (+7.7 pts).
12-Quarter Structural Regimes & Landmark Inflections12Q Structural Regimes & Inflections
Risk deteriorated materially (+30.0 pts), driven by new Relative Growth Weakness (+13.0 pts) and new Capex Efficiency Stress (+10.8 pts).
Business Resilience & Benchmark Context
Overall: STRONGPEER COMPARISON MATRIX
Ranked surveillance & credit risk comparison against sector peers
Stable
Stable
Stable
Stable
Watch
Watch
* Peer comparison is based on risk signals, not valuation or returns.
Unlock 5-Year Forensic Divergence Cockpit
Access multi-year visual divergence charts (EBITDA vs CFO Cash Gap, Receivables Decoupling Spread, and Debt vs FCF Burn) for Aarti Pharmalabs Limited.
FINANCIAL STATEMENTS
Working Capital & Forensic Monitor
Operating Cycle Disclosuresยท6 Fiscal Years
Working Capital Schedule (INR Cr)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
Trade Receivables(โน Cr) | 583 | 575 | 519 | 440 | โ | โ |
Inventories(โน Cr) | 640 | 588 | 643 | 602 | โ | โ |
Trade Payables(โน Cr) | 335 | 278 | 378 | 347 | โ | โ |
Net Working Capital(โน Cr) | 889 | 885 | 784 | 695 | โ | โ |
Working Capital / Sales(%) | 48.6% | 41.7% | 42.2% | 35.7% | โ | โ |
Cash Conversion & Operating Cycle (Days)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
Cash Conversion Cycle (CCC)(days) | 177d | 152d | 154d | 130d | โ | โ |
Debtor Days (DSO)(days) | 116d | 99d | 102d | 82d | โ | โ |
Inventory Days (DIO)(days) | 128d | 101d | 126d | 113d | โ | โ |
Creditor Days (DPO)(days) | 67d | 48d | 74d | 65d | โ | โ |
Forensic Accounting Monitor & Divergences
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
Receivable Growth vs Sales (ฮ)(%) | +15.3% | -3.6% | +22.6% | โ | โ | โ |
Inventory Growth vs Sales (ฮ)(%) | +22.9% | -23.0% | +11.4% | โ | โ | โ |
Asset Growth vs Sales (ฮ)(%) | +33.7% | -1.9% | +20.4% | -52.9% | โ | โ |
Earnings-to-Cash Divergence (PAT - CFO)(โน Cr) | -87 | -59 | 1 | -70 | 166 | 0 |
Accrual Ratio (Accruals / Avg Assets)(%) | -2.7% | -2.2% | 0.0% | -3.3% | 8.1% | โ |
Operating Cash Realisation (CFO / EBITDA)(%) | 115.0% | 91.9% | 72.0% | 100.9% | -21.3% | โ |
Capitalisation Intensity (CWIP / Assets)(%) | 18.6% | 21.7% | 7.2% | 6.3% | โ | โ |
Industry Intelligence
Pharmaceutical Sector KPIs| Operating Driver | Quarter | Current Value | Change (QoQ) | Change (YoY) | Industry Median |
|---|---|---|---|---|---|
Gross Margin โ | Q2 FY2027 | 45.2% | -780 bps โ Profitability contraction | -620 bps โ Profitability contraction | 64.0% |
Understanding Pharmaceutical KPIs
Concall & Management Takeaways
No investor earnings call transcripts transcribed for this scrip.
Earnings call intelligence is automatically populated when companies conduct quarterly earnings calls with institutional investors and publish transcripts.
Business quality remains strong.
Current forensic pressure is elevated and improving.
Key risks remain concentrated in growth sustainability and operating leverage.
The risk profile is Early Signals and currently improving. Recent structural triggers in growth sustainability suggest a building pressure on the underlying framework. Material forensic traces are visible in core structural metrics, indicating a progressive erosion of structural stability. Initial structural recovery is visible; monitor for a sustained return to resilience.
Market Expectation Engine
Investor Translation โข What the market price is expecting
Expectation EngineAt the current price of โน882, the market expects this company to grow its revenue by 34.9% every year for the next 5 years. If you think the company will grow faster than 34.9%, current market prices reflect a discount relative to that growth assumption.
Sentinel Takeaway:The market expects future growth in line with the company's historical delivery. Current market expectations appear balanced relative to the business's track record, representing standard expectation risk.
Using the Implied Revenue Model, the market is pricing AARTIPHARM for 34.9% implied revenue growth versus -2.1% observed 3Y revenue CAGR. Current expectations appear demanding, and trailing fundamentals provide moderate support.
Business Delivery Capacity
Performance quality vs historical benchmarksHistorical business performance currently provides limited support for the market's implied growth assumptions. Improvement in revenue growth and operating efficiency would strengthen expectation support.
WHY IS EXPECTATION RISK ELEVATED?
Valuation Context
WHAT MUST HAPPEN FOR CURRENT PRICE TO BE CORRECT?
| Assumption Metric | Required (To justify current price) | Historical Delivery (Average) | Fulfillment Assessment |
|---|---|---|---|
| Revenue Growth (CAGR) | 34.9% | -2.1% | Aggressive |
| Operating Margin (EBIT) | 14.8% | 15.2% | Achievable |
| Free Cash Flow Conversion | -46.0% | -21.4% | Achievable |
*Required metrics indicate the operating efficiency and revenue expansion parameters that must be sustained long-term to justify the current stock price.
The current valuation assumes business performance broadly in line with the company's historical record. Historical operating performance currently provides limited evidence that these expectations are sustainable. Continued revenue acceleration, stronger profitability and stronger cash generation would be required to justify current pricing.
Market Structure Methodology
Flagium separates Business Risk from Market Structure. Business analysis explains what is happening inside the company. Market Structure measures how investors are behaving through price trends, momentum, participation, and institutional activity. Divergences between the two often reveal important transitions before they become obvious.
The stock remains in a confirmed Stage 2 advancing phase. Institutional participation has also improved, reinforcing the constructive trend as momentum is accelerating. Current price action continues to support the prevailing advance.
What Is Driving Market Structure?
Price structure remains strong despite building fundamental risk.
Market Cycle Stage Analysis
Stan Weinstein 4-Stage CycleMomentum & Institutional Flow
Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics and research platform providing quantitative risk, forensic, and valuation analytics for informational and educational purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. These analytics do not constitute financial planning, investment advice, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.
๐ฌ Flagium Risk Brief โ Track forensic risks on AARTIPHARM & 3 market anomalies weekly
See a sample issue โ